What's on the Horizon for T-Cell Lymphoma Therapy?

By Swaminathan Iyer, MD, Chadi Nabhan, MD, MBA, FACP - Last Updated: September 14, 2023

Swaminathan Iyer, MD, of the University of Texas MD Anderson Cancer Center, joins Chadi Nabhan, MD, MBA, FACP, Host of The HemOnc Pulse, at the Eleventh Annual Meeting of the Society of Hematologic Oncology to discuss updates in T-cell lymphoma.

T-cell lymphoma represents one of the “last frontiers in lymphoma,” Dr. Iyer said.

However, there have been advances in understanding the genetics and classification of T-cell lymphoma.

“Genomics have played a huge role in a lot of other cancers,” he said. “T-cell lymphoma is one of the last few ones where we are actually able to molecularly classify.”

There have also been advances in therapy for T-cell lymphoma, Dr. Iyer said.

“Now we have epigenetically targeted therapies that are making a difference … I think we are seeing progress.”

Dr. Iyer and Dr. Nabhan also spoke about hematopoietic stem cell transplant and what might be on the horizon for chimeric antigen receptor (CAR) T-cell therapy in T-cell lymphoma.

“I think transplant is still going to play a large role in T-cell lymphoma until CAR-T is approved,” Dr. Iyer said.

Post Tags:SOHO 2023
Editorial Board